GlassScriptPhysician profile
Mallory Ann Smith
NPI 1346902038
$2,819.35
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.61 · 2022: $937 · 2023: $1,401 · 2024: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.46 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $425.82 | 2022-2024 | |
| Lundbeck LLC | $233.78 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $201.07 | 2022-2024 | Breztri, Airsupra |
| Pfizer INC. | $186.85 | 2022-2024 | |
| Lilly USA, LLC | $128.58 | 2021-2024 | Mounjaro, Zepbound |
| Bausch Health US, LLC | $116.36 | 2022-2023 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $115.77 | 2022-2023 | Rexulti |
| Currax Pharmaceuticals LLC | $99.36 | 2022-2024 | Contrave, Nexletol, Nexlizet |
| Glaxosmithkline, LLC. | $94.83 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $93.00 | 2023-2024 | |
| Astellas Pharma US INC | $86.18 | 2022-2023 | Veozah |
| Corium, LLC | $82.51 | 2022-2023 | Azstarys |
| Lucid Diagnostics INC. | $62.81 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $48.71 | 2023 | Ztlido |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.74 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Idorsia Pharmaceuticals US INC | $41.96 | 2022-2023 | Quviviq |
| Tris Pharma INC | $38.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.00 | 2022 | |
| Edwards Lifesciences Corporation | $35.45 | 2022 | |
| Boston Scientific Corporation | $31.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $30.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.84 | 2021 | |
| Quidel Corporation | $21.56 | 2022 | |
| Sanofi Pasteur INC. | $21.33 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $20.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2022 | |
| Alkermes, INC. | $15.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.